Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization
Tóm tắt
Từ khóa
Tài liệu tham khảo
Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–6.
Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, Lebwohl M. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72:961–7. e965
Edson-Heredia E, Zhu B, Lefevre C, Wang M, Barrett A, Bushe CJ, Cox A, Wu JJ, Maeda-Chubachi T. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using clinical practice research datalink. J Eur Acad Dermatol Venereol. 2015;29:955–63.
Famenini S, Sako EY, Wu JJ. Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors. Am J Clin Dermatol. 2014;15:45–50.
Fried RG, Friedman S, Paradis C, Hatch M, Lynfield Y, Duncanson C, Shalita A. Trivial or terrible? The psychosocial impact of psoriasis. Int J Dermatol. 1995;34:101–5.
Nguyen T, Wu JJ. Relationship between tumor necrosis factor-α inhibitors and cardiovascular disease in psoriasis: a review. Permanente J. 2014;18:49–54.
Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298:321–8.
Wu JJ, Choi YM, Bebchuk JD. Risk of myocardial infarction in psoriasis patients: a retrospective cohort study. J Dermatolog Treat. 2015;26:230–4.
Wu JJ, Nguyen TU, Poon K-YT, Herrinton LJ. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol. 2012;67:924–30.
Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401–7.
Armstrong AW, Reddy SB, Garg A. Novel approach to utilizing electronic health records for dermatologic research: developing a multi-institutional federated data network for clinical and translational research in psoriasis and psoriatic arthritis. Dermatol Online J. 2012;18(5):2.
Davison NJ, Warren RB, Mason KJ, McElhone K, Kirby B, Burden AD, Smith CH, Payne K, Griffiths CEM. Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study. Br J Dermatol. 2017;177(3):828–36.
Iskandar IY, Ashcroft DM, Warren RB, Yiu ZZ, McElhone K, Lunt M, Barker JN, Burden AD, Ormerod AD, Reynolds NJ, et al. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists biologic interventions register. Br J Dermatol. 2015;173(2):510–8.
Iskandar IYK, Ashcroft DM, Warren RB, Evans I, McElhone K, Owen CM, Burden AD, Smith CH, Reynolds NJ, Griffiths CEM. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists biologic interventions register (BADBIR). Br J Dermatol. 2017;176(5):1297–307.
Burden AD, Warren RB, Kleyn CE, McElhone K, Smith CH, Reynolds NJ, Ormerod AD, Griffiths CE. The British Association of Dermatologists’ biologic interventions register (BADBIR): design, methodology and objectives. Br J Dermatol. 2012;166(3):545–54.
Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat. 1996;5(3):299–314.
Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the Management of Psoriasis and Psoriatic Arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87–97.
Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180–5.
Levin AA, Gottlieb AB, Au SC. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. J Drugs Dermatol. 2014;13(7):848–53.
Evans C. Managed care aspects of psoriasis and psoriatic arthritis. Am J Manag Care. 2016;22(8 Suppl):s238–43.
Papoutsaki M, Costanzo A. Treatment of psoriasis and psoriatic arthritis. BioDrugs. 2013;27(Suppl 1):3–12.